Status:

COMPLETED

Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients

Lead Sponsor:

Vanderbilt University Medical Center

Collaborating Sponsors:

Teva Pharmaceuticals USA

Conditions:

Huntington Disease

Eligibility:

All Genders

21+ years

Phase:

NA

Brief Summary

Phase A: Recruit 50 patients with HD, and their caregivers, to complete a neuropsychiatric and quality of life battery of scales at baseline. Have these 50 patients complete a formal psychiatric asses...

Detailed Description

As presented to Phase A (control) patient participant: "If you are in this study, you will be asked to answer a series of online surveys assessing your psychiatric symptoms and quality of life in the...

Eligibility Criteria

Inclusion

  • Patient participants:
  • Diagnosed with HD, either through genetic testing or neurologist's clinical diagnosis
  • Patient has at least 1 neuropsychiatric symptom, as reported by their HD provider
  • 21 and older will be included, as symptoms of Juvenile HD (in patients 20 years old or less) can present differently
  • Presence of an eligible caregiver who can also participate in the study with them because several of the study measures require caregiver report
  • Caregivers:
  • 18 years or older
  • A caregiver will be defined as someone who lives with or has at least weekly contact with the HD patient

Exclusion

  • Patient participants:
  • 20 years old or younger
  • Greater than moderate impairment on dementia screening
  • Lack of a caregiver to provide collateral information and complete caregiver assessments will also be excluded
  • Caregivers:
  • Younger than 18 years old and/or have less than weekly contact with the HD patient
  • Clinical impression of incompetency to answer survey questions as determined by the Jessie Sellers, Nurse Practitioner, or the neurologist caring for the HD patient, then he or she will not be eligible to participate.

Key Trial Info

Start Date :

November 9 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 10 2023

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT03417583

Start Date

November 9 2018

End Date

October 10 2023

Last Update

November 15 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Vanderbilt Medical Center

Nashville, Tennessee, United States, 37232

Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients | DecenTrialz